(12) **Translation of European patent specification**

(11) **NO/EP 3113772 B1**

(19) NO

NORWAY

(51) Int Cl.

C07D 403/12 (2006.01)
A61K 31/415 (2006.01)
A61P 7/02 (2006.01)
C07D 231/14 (2006.01)
C07D 401/04 (2006.01)
C07D 401/14 (2006.01)
C07D 403/04 (2006.01)
C07D 405/12 (2006.01)
C07D 413/04 (2006.01)
C07D 413/12 (2006.01)
C07D 417/12 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.02.15
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.09.09
(86)	European Application Nr.	15759254.4
(86)	European Filing Date	2015.03.09
(87)	The European Application's Publication Date	2017.01.11
(30)	Priority	2014.03.07, US, 201461949808 P 2014.04.18, US, 201461981515 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Biocryst Pharmaceuticals, Inc., 4505 Emperor Blvd., Durham, North Carolina 27703, USA
(72)	Inventor	KOTIAN, Pravin L., 1139 Magnolia Run, Hoover, AL 35226, USA BABU, Yarlagadda S., 4836 Southlake Pkwy., Birmingham, AL 35244, USA WU, Minwan, 2709 Paden Trl., Vestavia Hills, AL 35226, USA CHINTAREDDY, Venkat R., 3134 Renfro Road, Vestavia Hills, AL 35216, USA KUMAR, V. Satish, 809 Mayapple Ct., Birmingham, AL 35244, USA ZHANG, Weihe, 2645 Manchester Court, Vestavia, AL 35226, USA
(74)	Agent or Attorney	Budde Schou A/S, Dronningens Tværgade 30, 1302 KØBENHAVN K, Danmark

(54) Title **TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS**

(56) References Cited:

WO-A1-98/28269
WO-A1-03/045912
WO-A2-02/00651
US-A1- 2004 171 649
US-A1- 2010 256 195
DONALD J. P. PINTO ET AL: "Factor Xa Inhibitors: Next-Generation Antithrombotic Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 17, 9 September 2010 (2010-09-09), pages 6243-6274, XP55061933, ISSN: 0022-2623, DOI: 10.1021/jm100146h
QUAN MIMI L ET AL: "Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoro methyl-N-[2-fl uoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phe nyl]-1H-pyrazole-5- carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 48, no. 6, 24 March 2005 (2005-03-24) , pages 1729-1744, XP002437749, ISSN: 0022-2623, DOI: 10.1021/JM0497949
DATABASE PUBCHEM [Online] 18 March 2017 'SCHEMBL11928476', XP055358143 Retrieved from NCBI Database accession no. CID 46245112

Patentkrav

1. Forbindelse, eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen velges fra gruppen som består av:



,


,


,


,


,


,


,

,

,

,

,

,

,

,

,

,










,

,

,

,

,

,

, -

,











,

,

,

,

,

,

,

,

,

,


,

,


,

,


,

,


,

,


,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

.


,

,

,

,

,

,

,

,


F3C
N
N
O
HN
NH2
HN
Ph

,


F3C
N
N
O
HN
NH2
HN
OCH3

,


F3C
N
N
O
HN
NH2
HN
OH

,


F3C
N
N
O
HN
NH2
HN
OH

,


F3C
N
N
O
HN
NH2
HN
NHCOCH3

,


F3C
N
N
O
F
HN
NH2
HN
NH2

,


F3C
N
N
O
F
HN
NH2
HN

,


F3C
N
N
O
F
HN
NH2
HN
O

,











,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,




, og

2. Forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen velges fra gruppen som består av:


,

,

,

,


,

,

,

,

,

,

,

,

,

,


F3C
O
N
N
HN
O
NH2

,


F3C
O
N
N
HN
OH
NH2

,


F3C
O
N
N
HN
HN
OH
NH2

,


F3C
O
F
N
N
HN
HN
O
Me
NH2

,


F3C
O
N
N
HN
HN
NH2
NH2

,


F3C
O
N
N
HN
O
NH2
NH2

,


F3C
O
N
N
HN
O
N
NH2

,



,


,


,


, og


.

3. Forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen velges fra gruppen som består av:



,


,


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

, ,


F3C
N
N
O
HN
F
HN
NH2
HN
CN

,


HO
O
N
N
H
N
F
O
HN
NH2

,


NC
N
N
H
N
F
O
NH2
CN
NH2

,


F3C
N
N
O
HN
CN
NH2
NH2

,


F3C
N
N
O
HN
NH2
NH2
CN

,


NC
N
N
O
HN
F
NH2
H2N
O
NH2

,


F3C
N
N
O
HN
F
O
H2N
H2N
CN

,


NC
N
N
H
N
F
O
HN
NH2

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,


,

,


,

,


,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,


, og

4. Forbindelsen ifølge krav 2, eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen velges fra gruppen som består av:


,

,

,

,

,

,

,

,



,



,



, og



.

5. Forbindelsen ifølge krav 2, eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen velges fra gruppen som består av:


,

,

,

,

,

,


,

,


,

,


, og


.

6. Forbindelsen ifølge krav 2, eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen velges fra gruppen som består av



,


,




: og .

7. Forbindelsen ifølge krav 2, eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen velges fra gruppen som består av



,


,




, og .

8. Forbindelsen ifølge krav 2, eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen velges fra gruppen som består av


,

,

,


. og

9. Forbindelsen ifølge krav 2, eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen velges fra gruppen som består av



,



,





, og .

10. Forbindelsen ifølge krav 2, eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen velges fra gruppen som består av



,



,



, og



.

11. Forbindelsen ifølge krav 2, eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen velges fra gruppen som består av



,



,





, og

12. Forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen har formelen:



13. Forbindelsen ifølge krav 12, hvori forbindelsen er (+)-enantiomeren.

14. Forbindelsen ifølge krav 12, hvori forbindelsen er (-)-enantiomeren.

15. Forbindelsen ifølge et hvilket som helst av kravene 12−14, hvori forbindelsen er et hydrokloridsalt.

16. Forbindelsen ifølge et hvilket som helst av kravene 12−14, hvori forbindelsen er et bis(hydroklorid)salt.

17. Farmasøytisk sammensetning, omfattende en forbindelse ifølge et hvilket som helst av kravene 1−16, eller et farmasøytisk akseptabelt salt derav, og en farmasøytisk akseptabel bærer, eventuelt hvori den farmasøytiske sammensetningen er formulert for parenteral administrering eller oral administrering, eventuelt hvori den

farmasøytiske sammensetningen er formulert for den profylaktiske eller terapeutiske behandlingen av en sykdom eller tilstand der det er ønskelig å redusere plasma-kallikrein-aktivitet;
hvori sykdommen eller tilstanden velges fra gruppen som består av hjerneslag, betennelse, reperfusjonsskade, akutt hjerteinfarkt, dyp venetrombose, tilstand etter fibrinolytisk behandling, angina, ødem, angioødem, arvelig angioødem, sepsis, leddgikt, blødning, blodtap under kardiopulmonal bypass, inflammatorisk tarmsykdom, diabetes mellitus, retinopati, diabetisk retinopati, diabetisk makulaødem, diabetisk makuladegenerasjon, aldersrelatert makulaødem, aldersrelatert makuladegenerasjon, proliferativ retinopati, nevropati, hypertensjon, hjerneødem, økt albuminutskillelse, makroalbuminuri og nefropati.

18. Forbindelse ifølge et hvilket som helst av kravene 1−16, eller et farmasøytisk akseptabelt salt derav, for anvendelse i behandlingen eller forebyggingen av en sykdom eller tilstand der det er ønskelig å redusere plasma-kallikrein-aktivitet; hvori sykdommen eller tilstanden velges fra gruppen som består av hjerneslag, betennelse, reperfusjonsskade, akutt hjerteinfarkt, dyp venetrombose, tilstand etter fibrinolytisk behandling, angina, ødem, angioødem, arvelig angioødem, sepsis, leddgikt, blødning, blodtap under kardiopulmonal bypass, inflammatorisk tarmsykdom, diabetes mellitus, retinopati, diabetisk retinopati, diabetisk makulaødem, diabetisk makuladegenerasjon, aldersrelatert makulaødem, aldersrelatert makuladegenerasjon, proliferativ retinopati, nevropati, hypertensjon, hjerneødem, økt albuminutskillelse, makroalbuminuri og nefropati.

19. Forbindelsen for anvendelse ifølge krav 18, hvori sykdommen eller tilstanden er angioødem.

20. Forbindelsen for anvendelse ifølge krav 18, hvori sykdommen eller tilstanden er arvelig angioødem.

21. Forbindelse ifølge et hvilket som helst av kravene 1−16, eller et farmasøytisk akseptabelt salt derav, for anvendelse som et medikament.